Match each type 2 diabetes mellitus medication to its most characteristic adverse effect or clinical contraindication.
- MetforminAssociated with gastrointestinal distress and carries a risk of lactic acidosis in patients with severe chronic kidney disease.
- EmpagliflozinAssociated with an increased risk of euglycemic diabetic ketoacidosis and vulvovaginal candidiasis.
- SemaglutideMay cause significant nausea and vomiting, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
- PioglitazoneCarries a risk of weight gain, fluid retention, and exacerbation of underlying heart failure.
- GlimepirideCarries a high risk of hypoglycemia, particularly in older patients, and causes weight gain.
Cevap
Metformin matches with GI distress/lactic acidosis; Empagliflozin matches with euglycemic DKA/candidiasis; Semaglutide matches with nausea/medullary thyroid cancer risk; Pioglitazone matches with fluid retention/heart failure; Glimepiride matches with high risk of hypoglycemia.
Each antidiabetic medication class possesses a unique mechanism of action that corresponds to specific adverse effects. Metformin causes lactic acidosis in renal failure. SGLT2 inhibitors (empagliflozin) cause genitourinary infections and euglycemic DKA due to glycosuria. GLP-1 agonists (semaglutide) cause nausea and are contraindicated in medullary thyroid carcinoma. Thiazolidinediones (pioglitazone) cause fluid retention that worsens heart failure. Sulfonylureas (glimepiride) cause weight gain and hypoglycemia by stimulating insulin secretion.
Adım Adım Çözüm
Anahtar Kavram
Adverse effects and clinical contraindications of type 2 diabetes mellitus pharmacotherapy.